A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424 (Dienogest 2 mg / Ethinyl Estradiol 0.02 mg) During 13 Cycles
Latest Information Update: 20 Nov 2023
At a glance
- Drugs Ethinylestradiol/dienogest (Primary)
- Indications Pregnancy
- Focus Registrational; Therapeutic Use
- Sponsors Insud Pharma
Most Recent Events
- 13 Nov 2023 Status changed from active, no longer recruiting to completed.
- 08 Aug 2023 Planned End Date changed from 30 Jun 2023 to 30 Sep 2023.
- 14 Sep 2022 Planned End Date changed from 1 Oct 2021 to 30 Jun 2023.